Abstract
Humans have always lived with tubercle bacilli. Host susceptibility – both inherited and acquired – determines whether an individual infected with Mycobacterium tuberculosis will eventually fall ill and develop tuberculosis (TB). After infection with M. tuberculosis, a latent TB infection may ensue reflected by immune recognition of specific antigenic epitopes expressed by M. tuberculosis – the Region of Difference 1 proteins ESAT-6 and CFP-10 leading to interferon gamma release in vitro. Multi-Drug-Resistant TB has emerged as an enormous infectious threat in certain regions in the world, and the Acquired immunodeficiency by co-infection with HIV has accelerated the TB epidemic even further. A paradoxical response – or Immune Response Inflammatory Syndrome in the context of treatment of HIV co-infection - is an increased inflammatory reaction during effective reduction in the bacterial load. This should be differentiated from treatment failure. A huge challenge is to develop novel markers that can differentiate paradoxical responses from treatment failure. We discuss the role of protection of vaccines – especially BCG, iron metabolism and the role of vitamin D.
Keywords: Mycobacterium tuberculosis, immune response, interferon gamma, BCG, vitamin D, iron, immune response inflammatory syndrome, Multi-Drug Resistant TB (MDR-TB), sputum smear microscopy, Mycobactin
Current Pharmaceutical Design
Title: Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection
Volume: 17 Issue: 27
Author(s): Richard van Altena, Sridevi Duggirala, Matthias I. P.Groschel and Tjip S. van der Werf
Affiliation:
Keywords: Mycobacterium tuberculosis, immune response, interferon gamma, BCG, vitamin D, iron, immune response inflammatory syndrome, Multi-Drug Resistant TB (MDR-TB), sputum smear microscopy, Mycobactin
Abstract: Humans have always lived with tubercle bacilli. Host susceptibility – both inherited and acquired – determines whether an individual infected with Mycobacterium tuberculosis will eventually fall ill and develop tuberculosis (TB). After infection with M. tuberculosis, a latent TB infection may ensue reflected by immune recognition of specific antigenic epitopes expressed by M. tuberculosis – the Region of Difference 1 proteins ESAT-6 and CFP-10 leading to interferon gamma release in vitro. Multi-Drug-Resistant TB has emerged as an enormous infectious threat in certain regions in the world, and the Acquired immunodeficiency by co-infection with HIV has accelerated the TB epidemic even further. A paradoxical response – or Immune Response Inflammatory Syndrome in the context of treatment of HIV co-infection - is an increased inflammatory reaction during effective reduction in the bacterial load. This should be differentiated from treatment failure. A huge challenge is to develop novel markers that can differentiate paradoxical responses from treatment failure. We discuss the role of protection of vaccines – especially BCG, iron metabolism and the role of vitamin D.
Export Options
About this article
Cite this article as:
van Altena Richard, Duggirala Sridevi, I. P.Groschel Matthias and S. van der Werf Tjip, Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470228
DOI https://dx.doi.org/10.2174/138161211797470228 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Multivariate Calibration: A Powerful Tool in Pharmaceutical Analysis
Current Pharmaceutical Analysis The State of the Art in Anti-Malarial Drug Discovery and Development
Current Topics in Medicinal Chemistry Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Nonprofit Pharma: Solutions to What Ails the Industry
Current Medicinal Chemistry Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation
Current Medicinal Chemistry New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
Current Pharmaceutical Design Smart Phones As a Viable Data Collection Tool in Low-resource Settings: Case Study of Rwandan Community Health Workers
Neuroscience and Biomedical Engineering (Discontinued) Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Calcium Oxide Catalyzed Synthesis of Chalcone Under Microwave Condition
Current Microwave Chemistry Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or Selective Inhibitors?
Mini-Reviews in Medicinal Chemistry Recent Advances in Peptide Nucleic Acids as Antibacterial Agents
Current Medicinal Chemistry Recent Developments in Azole Compounds as Antitubercular Agent
Mini-Reviews in Organic Chemistry Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Attack on the Scourge of Tuberculosis: Patented Drug Targets
Recent Patents on Anti-Infective Drug Discovery